Wilms' tumour (WT; nephroblastoma), a kidney neoplasm, is one of the most frequently occurring solid tumours of childhood. It arises from the developing kidney by genetic and epigenetic changes that lead to the abnormal proliferation of renal stem cells (metanephric blastema). WT serves as a paradigm for understanding the relationship between loss of developmental control and gain of tumourigenic potential. In particular, loss of function of tumour suppressor genes has been implicated in the development of WT, and the Wilms' tumour suppressor gene WT1 (at chromosome 11p13) was the second tumour suppressor gene to be cloned, after the retinoblastoma gene RB-1. WT1 plays an essential role in kidney development, but is mutated in only approximately 20% of WTs, which suggests that further lesions and genetic loci are involved in Wilms' tumourigenesis. Other chromosomal regions associated with WT include 7p, 11p15, 16q and 17q. Although many of these loci probably contain tumour suppressor genes, imprinted genes (genes showing expression of only one parental allele) and oncogenes have also been implicated in WT. Some loci have been shown to be associated with particular clinical outcomes, suggesting that they might be used to determine prognosis, and especially to identify poor prognostic subgroups that can be targeted for aggressive and/or novel therapies.
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Wilms' tumour (WT) is an embryonal renal neoplasm ( Fig. 1 ) and is one of the commonest solid tumours of childhood, affecting ~1 in 10 000 children (rates vary slightly between different racial groups), typically between the ages of 2 and 4 years. It has a high cure rate (~85%), which has been achieved using a combination of surgery, chemotherapy and radiotherapy. However, 15% of affected children still die from their disease, and present therapies can have serious short-and long-term side effects. No strong environmental factors have been implicated in WT development, but there are several predisposing syndromes that confer a greatly increased risk of developing WT, indicating a major role for genetic factors in Wilms' tumourigenesis (Ref. 1) . This review briefly describes the biology of WT and then discusses recent work on the genetic and epigenetic changes underlying this disease.
Biology of WT
WT arises from the developing kidney. The definitive mammalian kidney, the metanephros, develops by an inductive interaction between the ureteric bud (which goes on to form the collecting duct system) and the metanephric blastema (which goes on to form the nephrons and connective tissue) ( Fig. 2 ) (Ref. 2) . The blastema is induced to differentiate to form both epithelial components (which will give rise to nephrons) and stromal components (which make up the connective tissue) in the kidney (Fig. 2) , with cells that are not induced to differentiate undergoing programmed cell death (apoptosis) (Ref. 3) . Kidney development is complete by 36 weeks of gestation in humans. WT is presumed to arise because of the failure of the metanephric blastema to undergo its normal developmental pathway. However, differentiation potential is often partly maintained in WTs, and is manifested as the classical 'triphasic histology' (Fig. 3b) , in which nests of blastema are seen together with areas of epithelial tubules and stroma (Ref. 4) . Other histological variants of WT occur in which one cell type predominates [e.g. blastemalpredominant (Fig. 3c ) and stromal-predominant (Fig. 3d) variants] .
WT is thought to develop via a premalignant stage, the 'nephrogenic rest', in which areas of undifferentiated blastema persist after 36 weeks gestation (Ref. 5) . Rests are seen in less than 1% of routine autopsies of infants, but are found adjacent to ~30% of sporadic WTs and more frequently in predisposing syndromes (see below). The majority of nephrogenic rests regress, but some undergo malignant transformation, grow in size and might ultimately go on to form a WT ( 
Current therapies for WT
Treatment of WT usually involves removal of the whole affected kidney, comprising both the tumour and the attached remaining normal kidney (complete nephrectomy -see Fig. 1 ). The patient then receives adjuvant cytotoxic chemotherapy, and sometimes also radiotherapy. The exact treatment protocol depends on prognostic factors such as extent of spread of the tumour (stage) and whether the tumour has a potentially aggressive phenotype as judged by its histology (e.g. anaplasia -see 
Genetics of WT
Studies of patients who have syndromes that predispose to WT have been pivotal in identifying genetic factors involved in WT development. Patients with these syndromes tend to develop multiple tumours, either as tumours in both kidneys (bilateral disease) or as multiple tumours in one kidney (multifocal disease, as shown in Fig. 1 ). These tumours occur at an earlier age of onset than in sporadic (non-predisposed) cases, which normally present with a single tumour at a later age. The cases of genetic predisposition led Knudson to extend his 'two-hit' model of retinoblastoma to include WT, suggesting that two rate-limiting steps were essential for WT development (Ref. 6) . Another aspect of the model was a prediction of large numbers of inherited cases of WT. Although this prediction turned out 
WT genes
The discovery of cytogenetic abnormalities in syndromes predisposing to WT [e.g. 11p13 deletions in the WAGR syndrome (Ref. 
WT1 (chromosome 11p13)
The existence of a tumour suppressor gene on chromosome 11 was suggested by the finding of 11p13 deletions in the WAGR syndrome (Ref. 7) and 11p LOH in sporadic WTs ( 
WT1 gene structure
The WT1 gene is ~50 kb long (Refs 15, 16, 17) and encodes multiple 52-56 kDa protein isoforms Two 'hits' (mutations) that inactivate both alleles of a tumour suppressor gene on the short arm of chromosome 11 are needed for Wilms' tumour to develop. Gross genetic changes affecting this part of chromosome 11 can be monitored by examining a polymorphic marker ('A' in this figure) that lies close to the tumour suppressor gene. The first hit is usually a point mutation or small deletion, shown as a cross on the paternal chromosome. This does not affect the integrity of the chromosome, so both alleles of the polymorphic marker (conventionally named A1 and A2) are retained. The second hit often involves a large-scale chromosomal event, such as loss of a chromosome arm -in this case the loss of the short arm of the maternal chromosome. This leads to the loss of A2, which is detected as the loss of a band on the Southern blot of tumour DNA -see panel 'b'. Note that in Wilms' tumour it is always the allele on the maternal chromosome 11 that is lost. This reflects the presence of imprinted genes on this part of chromosome 11 (see text). (b) Southern blot of DNA extracted from the normal tissue and tumour of a patient with Wilms' tumour, and from the blood of the patient's father and mother. The DNA was cut with a restriction enzyme and probed with a radioactive DNA sequence that detects a polymorphism on the short arm of chromosome 11. This polymorphism has two possible alleles: A1 and A2. The patient's tumour shows loss of A2 compared with normal tissue. It can be seen that this was the allele that the patient inherited from the mother, indicating that it is the maternal allele that is lost in Wilms' tumour. [The father was heterozygous for this polymorphism (A1A2), whereas the mother was homozygous (A2A2)] (fig004kbb). 
Biological effects of WT1

Mutations in WT1
In humans, deletion of one allele of WT1 causes genitourinary abnormalities in the WAGR syndrome, whereas heterozygous germline missense mutations lead to the more severe defects observed in DDS, probably because of a dominant-negative effect of the mutant protein (Ref. 
Control of WT1 expression
Other loci
To date, WT1 is the only cloned WT gene. Since it is mutated in only 20% of tumours, other loci have been investigated to attempt to account for the development of the remainder of WT cases.
Chromosome 11p15
LOH at 11p occurs in 40-50% of WTs (Ref. 4) , and, in some of these, the loss is limited to the 11p15 region (Refs 53, 54), implicating a further tumour suppressor gene, WT2, on 11p. In addition, the gene(s) associated with the WT-predisposing disease BWS map to 11p15 (Ref. 55 ). 11p15 contains a cluster of imprinted genes that have been shown to be involved in WT both by LOH and by epigenetic changes (see below) (Ref. 56 ).
Chromosomes 16q and 1p
Chromosome 16q LOH occurs in about 20% of WTs and is associated with a poor prognosis. 1p LOH occurs less often and the evidence for prognostic significance is marginal (Ref. 57 
Chromosome 7p
This locus was implicated in WT by investigations of a patient with WT who also had an unusual set of congenital abnormalities and a constitutional balanced translocation (in which parts of chromosomes are swapped around, with no visible loss of genetic material) between chromosomes 1 and 7: t(1;7)(q42;p15) (Ref. 59) . Subsequent LOH studies suggested that there is a tumour suppressor gene on 7p that is involved in at least 10% of WTs (Refs 60, 61, 62).
Inherited WT
In rare cases, WT is inherited as an autosomal dominant trait and linkage has been reported in these families to chromosomes 17q (Ref. 
Other genetic abnormalities
Epigenetics
The genetic loci listed above are involved in WT via classical mutational and cytogenetic mechanisms. However, it has recently become apparent that epigenetic changes, particularly alterations in DNA methylation, also occur on chromosome 11, both at 11p13 and at 11p15. These changes mainly involve imprinted genes.
Imprinted genes
Imprinted genes are those that have an epigenetic mark applied during gametogenesis, resulting in the expression of only one parental allele 
Epigenetic changes at 11p15
Involvement of imprinted genes in WT was first indicated by the discovery that LOH at 11p almost always involved the loss of the maternal allele (Fig. 4) (Refs 75, 76, 77, 78 ). This could be driven by the necessity either to lose a maternally expressed growth inhibitory gene or to retain a paternally expressed growth factor (Ref. 79). A cluster of imprinted genes has now been described at 11p15, containing both the paternally expressed growth factor IGF2, and the maternally expressed growth-inhibitory genes H19 and CDKNIC (p57 (Refs 82, 83) . Methylation of the DMR 5' of H19 inactivates a chromatin boundary, allowing access of IGF2 to a common set of enhancers, which leads to IGF2 expression from that allele (Refs 84, 85) . H19-independent control of IGF2 expression has also been suggested by the discovery of an antisense RNA from IGF2 that is overexpressed in WT (Ref. 86) ; however, the function of IGF2 antisense RNA is unclear at present. These results suggest that LOH at 11p15 (which usually involves duplication of the retained paternal copy of chromosome 11p15) and relaxation of imprinting both lead to the overexpression of a growth-promoting gene (IGF2) and the loss of expression of growthinhibitory genes (H19 and CDKNIC). Such aberrant expression of growth-promoting and growth-inhibitory genes could give fetal kidney cells a growth advantage, resulting in tumourigenesis. Epigenetic lesions in H19 are detectable in normal kidney tissue adjacent to WTs, and in premalignant lesions (nephrogenic rests). This suggests that imprinting changes are a relatively early event in tumourigenesis (Refs 82, 87, 88) .
Altered imprinting of the 11p15 region is also involved in the fetal overgrowth syndrome BWS, where patients exhibit organomegaly and increased risk of childhood cancer, especially WT (Ref. 55) . Familial cases of BWS map to 11p15, and some sporadic cases have chromosomal abnormalities involving the same region. Parent-of-origin effects are seen in each of the genetic abnormalities associated with BWS: preferential maternal transmission of inherited BWS and, in sporadic cases, paternal uniparental disomy (i.e. both copies of 11p15 are derived from the father's chromosomes), paternally derived chromosome duplications, and maternally derived chromosome translocations (Ref. 55 
Epigenetic changes at 11p13
The human WT1 antisense promoter region, on chromosome 11p13, was shown to be aberrantly hypermethylated in some cases of breast cancer (Ref. 92) , suggesting that epigenetic control of this region might play an important role in some cancers. Recently, it was demonstrated that the antisense regulatory region was a DMR: the maternal allele was methylated and the paternal allele was unmethylated in normal kidney (Ref. 51) . Consistent with this, WT1 antisense RNA is imprinted in normal kidney, with only the paternal allele being expressed (Ref. 51) . In WTs with no LOH, two hypomethylated alleles were observed instead of one methylated and one unmethylated allele, and both alleles were expressed, demonstrating relaxation of imprinting. By contrast, non-Wilms' renal tumours did not exhibit hypomethylation of both alleles, but exhibited a degree of hypermethylation, indicating that tumour-specific epigenetic variations occur at the WT1 locus (Ref. 51).
Outstanding research questions: the molecular pathogenesis of WT
Analysis of WT1 mutations in WTs, together with the data discussed above, indicate that multiple loci are involved in WT development. This is in marked contrast to retinoblastoma, which involves just one rate-limiting genetic alteration: inactivation of the retinoblastoma gene RB-1 (Ref. 93) . The early age of onset of WT shows that there are likely to be few ratelimiting genetic steps, in contrast to the multiple steps required for the development of adult tumours. Thus, many of the loci implicated in WT development are probably alternative loci, and inactivation of any one might be sufficient to initiate tumourigenesis, with further genetic and epigenetic changes being involved in tumour progression. Identifying subsets of WTs containing specific genetic or epigenetic changes expert reviews in molecular medicine and correlating these with biological properties is one obvious avenue of research to pursue. Thus far, only a few such correlations have been proposed, such as the presence of WT1 mutations in stromal-predominant WTs (Fig. 3d) (Ref. 94) , and the presence of p53 mutations in anaplastic WTs (Fig. 3e) (Refs 44, 67) .
The sequence of genetic events in Wilms' tumourigenesis has begun to be unravelled by studying the alterations present in premalignant nephrogenic rests. For instance, genetic and epigenetic changes at 11p (LOH, WT1 mutation, loss of imprinting) are found in nephrogenic rests, whereas LOH at 16q is not (Refs 41, 42, 86, 87) . This implies that genetic and epigenetic events at 11p are initiating events in WT development, whereas 16q alterations are involved in later progression to a more aggressive phenotype. This is consistent with 16q LOH being associated with a poor prognosis in WT (Ref. 57) . Similarly, p53 mutation is associated with a poor prognosis and might therefore be predicted to be a late event (Ref. 66) .
The various genes implicated in WT development could be involved in separate pathways (e.g. control of proliferation versus differentiation or apoptosis). Alternatively, they could all be inter-related, for example as targets for WT1, or as controllers of WT1 expression, or as proteins that interact with the WT1 protein. For 16q and WT1, some indication of which of these theories applies comes from the data on tumour progression. Thus, the 16q loci/ genes are unlikely to be part of the same pathway as WT1, because they are involved at different stages of tumourigenesis. Recent data on β-catenin mutations have shown that they are frequently associated with WT1 mutations in WTs (Ref. 95) , suggesting that WT1 and β-catenin mutations affect two different biochemical pathways.
The only way to be certain about the biochemical pathways these genes are involved in is to study their biological functions. This means that to gain a full understanding of WT development we must accomplish the following objectives: (1) clone all the genes involved; (2) determine how frequently they are mutated in WTs and at what progression stage; and (3) find out their biological and biochemical functions. With the near completion of the human genome project, the first two objectives should be attainable in the next few years. The third objective is much more difficult, and it is instructive to consider that although WT1 was cloned ten years ago, there is still controversy as to its essential biochemical function.
Knockout and transgenic mice will be very useful for studying the biology of WT genes but, for many studies, cell culture systems would be advantageous. In contrast to our advanced knowledge of WT genetics, we know little or nothing about the cell biology of WT. The only true WT cell lines in existence are derived from anaplastic tumours (an aggressive WT subtype) that represent a tiny fraction of WTs (Ref. 96 , and K. Brown, unpublished). Thus, it has not even been possible to test the tumour suppressor activity of WT1 in a cell line containing a WT1 mutation. It is therefore essential not only to isolate the critical WT genes, but also to develop systems with which to study the biological role of WT genes in normal nephrogenesis and how this is altered in WT development.
Conclusions and future prospects
It is now clear that WT development involves several, probably alternative, genetic pathways, but there is still an incomplete picture as to the identity of most of these genes, or the mechanisms by which they are controlled. However, the recent advances in human molecular genetics should soon enable a complete description of molecular defects in individual WTs. This should allow the stratification of WTs into good and poor prognosis groups, so that treatment can be targeted more effectively. It is especially important to be able to identify those patients who appear to have a good prognosis by conventional criteria, but who relapse and die when treated by what seemed the most appropriate regimen at the time of diagnosis.
The ultimate aim of all this work must be to develop effective, specific therapies that avoid the harmful side effects of present-day treatments. In view of the existing high cure rate for WT, any novel therapies will have to be demonstrably superior in all respects. A detailed knowledge of the molecular pathogenesis of WT is essential if we are to identify the biochemical targets for new methods of treatment. 
